Logo image of MGTX

MEIRAGTX HOLDINGS PLC (MGTX) Stock Fundamental Analysis

NASDAQ:MGTX - Nasdaq - KYG596651029 - Common Stock - Currency: USD

8.17  -0.16 (-1.92%)

After market: 8.17 0 (0%)

Fundamental Rating

2

Taking everything into account, MGTX scores 2 out of 10 in our fundamental rating. MGTX was compared to 550 industry peers in the Biotechnology industry. MGTX has a bad profitability rating. Also its financial health evaluation is rather negative. MGTX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MGTX had negative earnings in the past year.
In the past year MGTX has reported a negative cash flow from operations.
MGTX had negative earnings in each of the past 5 years.
In the past 5 years MGTX always reported negative operating cash flow.
MGTX Yearly Net Income VS EBIT VS OCF VS FCFMGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -74.70%, MGTX is doing worse than 66.55% of the companies in the same industry.
MGTX has a Return On Equity of -505.54%. This is in the lower half of the industry: MGTX underperforms 78.00% of its industry peers.
Industry RankSector Rank
ROA -74.7%
ROE -505.54%
ROIC N/A
ROA(3y)-40.41%
ROA(5y)-32.41%
ROE(3y)-129.61%
ROE(5y)-91.21%
ROIC(3y)N/A
ROIC(5y)N/A
MGTX Yearly ROA, ROE, ROICMGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Gross Margin of MGTX (27.50%) is better than 73.45% of its industry peers.
The Profit Margin and Operating Margin are not available for MGTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGTX Yearly Profit, Operating, Gross MarginsMGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

1

2. Health

2.1 Basic Checks

MGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
MGTX has more shares outstanding than it did 1 year ago.
MGTX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MGTX is higher compared to a year ago.
MGTX Yearly Shares OutstandingMGTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MGTX Yearly Total Debt VS Total AssetsMGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MGTX has an Altman-Z score of -4.57. This is a bad value and indicates that MGTX is not financially healthy and even has some risk of bankruptcy.
MGTX's Altman-Z score of -4.57 is in line compared to the rest of the industry. MGTX outperforms 41.09% of its industry peers.
A Debt/Equity ratio of 2.22 is on the high side and indicates that MGTX has dependencies on debt financing.
MGTX's Debt to Equity ratio of 2.22 is on the low side compared to the rest of the industry. MGTX is outperformed by 81.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.22
Debt/FCF N/A
Altman-Z -4.57
ROIC/WACCN/A
WACC10.61%
MGTX Yearly LT Debt VS Equity VS FCFMGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 1.53 indicates that MGTX should not have too much problems paying its short term obligations.
The Current ratio of MGTX (1.53) is worse than 81.45% of its industry peers.
MGTX has a Quick Ratio of 1.51. This is a normal value and indicates that MGTX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.51, MGTX is not doing good in the industry: 80.91% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.51
MGTX Yearly Current Assets VS Current LiabilitesMGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for MGTX have decreased strongly by -15.42% in the last year.
Looking at the last year, MGTX shows a very strong growth in Revenue. The Revenue has grown by 203.31%.
Measured over the past years, MGTX shows a very strong growth in Revenue. The Revenue has been growing by 20.15% on average per year.
EPS 1Y (TTM)-15.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-59.37%
Revenue 1Y (TTM)203.31%
Revenue growth 3Y-4.07%
Revenue growth 5Y20.15%
Sales Q2Q%176.33%

3.2 Future

Based on estimates for the next years, MGTX will show a very strong growth in Earnings Per Share. The EPS will grow by 35.37% on average per year.
The Revenue is expected to grow by 99.86% on average over the next years. This is a very strong growth
EPS Next Y61.79%
EPS Next 2Y43.23%
EPS Next 3Y17.37%
EPS Next 5Y35.37%
Revenue Next Year700.48%
Revenue Next 2Y342.91%
Revenue Next 3Y128.45%
Revenue Next 5Y99.86%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MGTX Yearly Revenue VS EstimatesMGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
MGTX Yearly EPS VS EstimatesMGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 74.51, which means the current valuation is very expensive for MGTX.
Based on the Price/Forward Earnings ratio, MGTX is valued cheaply inside the industry as 88.73% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.34, MGTX is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 74.51
MGTX Price Earnings VS Forward Price EarningsMGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGTX Per share dataMGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

MGTX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as MGTX's earnings are expected to grow with 17.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.23%
EPS Next 3Y17.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MGTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEIRAGTX HOLDINGS PLC

NASDAQ:MGTX (8/15/2025, 8:00:01 PM)

After market: 8.17 0 (0%)

8.17

-0.16 (-1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners44.22%
Inst Owner Change-0.33%
Ins Owners4.27%
Ins Owner Change2.73%
Market Cap656.62M
Analysts83.33
Price Target28.05 (243.33%)
Short Float %7.37%
Short Ratio7.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.86%
Min EPS beat(2)-2.74%
Max EPS beat(2)12.47%
EPS beat(4)1
Avg EPS beat(4)-19.81%
Min EPS beat(4)-86.27%
Max EPS beat(4)12.47%
EPS beat(8)3
Avg EPS beat(8)-41.14%
EPS beat(12)4
Avg EPS beat(12)-33.13%
EPS beat(16)6
Avg EPS beat(16)-23.19%
Revenue beat(2)1
Avg Revenue beat(2)620.32%
Min Revenue beat(2)-57.41%
Max Revenue beat(2)1298.04%
Revenue beat(4)2
Avg Revenue beat(4)425.38%
Min Revenue beat(4)-97.15%
Max Revenue beat(4)1298.04%
Revenue beat(8)3
Avg Revenue beat(8)196.92%
Revenue beat(12)4
Avg Revenue beat(12)114.93%
Revenue beat(16)8
Avg Revenue beat(16)131.13%
PT rev (1m)19.57%
PT rev (3m)16.53%
EPS NQ rev (1m)1.23%
EPS NQ rev (3m)-3.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-3425%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-42.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 74.51
P/S 19.03
P/FCF N/A
P/OCF N/A
P/B 19.84
P/tB 20.31
EV/EBITDA N/A
EPS(TTM)-2.32
EYN/A
EPS(NY)0.11
Fwd EY1.34%
FCF(TTM)-1.36
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0.43
BVpS0.41
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.7%
ROE -505.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.5%
FCFM N/A
ROA(3y)-40.41%
ROA(5y)-32.41%
ROE(3y)-129.61%
ROE(5y)-91.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 2.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.47%
Cap/Sales 14.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 1.51
Altman-Z -4.57
F-Score3
WACC10.61%
ROIC/WACCN/A
Cap/Depr(3y)233.72%
Cap/Depr(5y)368.57%
Cap/Sales(3y)147.08%
Cap/Sales(5y)142.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-59.37%
EPS Next Y61.79%
EPS Next 2Y43.23%
EPS Next 3Y17.37%
EPS Next 5Y35.37%
Revenue 1Y (TTM)203.31%
Revenue growth 3Y-4.07%
Revenue growth 5Y20.15%
Sales Q2Q%176.33%
Revenue Next Year700.48%
Revenue Next 2Y342.91%
Revenue Next 3Y128.45%
Revenue Next 5Y99.86%
EBIT growth 1Y-4.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year164.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.34%
OCF growth 3YN/A
OCF growth 5YN/A